Nebilet Hct (Hydrochlorothiazide, Nebivolol)

Nebivolol, the active ingredient in Nebilet HCT, is a beta‑adrenergic blocker presented as a tablet for oral use. It treats hypertension, often in combination with hydrochlorothiazide, and is indicated for adult patients requiring blood pressure control.

GNH USA supplies Nebilet HCT as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebilet HCT is used as an antihypertensive agent that lowers blood pressure through combined beta‑blockade and diuretic action.

- Hypertension: reduces systolic and diastolic pressure by decreasing cardiac output and plasma volume. - Essential hypertension: improves long‑term blood pressure control when monotherapy is insufficient. - Isolated systolic hypertension: helps achieve target systolic values in older adults.

Nebilet HCT may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances such as low potassium - Cold extremities

Serious or Rare Side Effects: - Severe hypotension - Acute gout attacks - Pancreatitis - Allergic reactions including rash or angioedema - Significant electrolyte imbalance (e.g., hyponatremia, hypokalemia)

Before initiating Nebilet HCT, clinicians should evaluate patient history and monitor relevant parameters.

- Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function: assess creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolytes: check serum potassium and sodium levels regularly. - Diabetes: monitor blood glucose as beta‑blockade may mask hypoglycaemia symptoms. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Store at ambient temperature: keep in the original pack, protect from moisture.

Nebilet HCT can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Other antihypertensives (e.g., ACE inhibitors, ARBs): risk of additive hypotension. - NSAIDs: may blunt diuretic efficacy and raise blood pressure. - Potassium‑sparing diuretics or supplements: increase risk of hyperkalaemia. - Strong CYP2D6 inhibitors (e.g., fluoxetine): raise nebivolol plasma levels. - Lithium: thiazide component can raise lithium concentrations.

Moderate Interactions (Monitor Closely): - Digoxin: monitor serum levels due to possible electrolyte changes. - Antidiabetic agents: enhanced hypoglycaemia risk; adjust glucose monitoring. - Alcohol: may exacerbate dizziness and hypotension. - Anticholinergic drugs: may increase risk of urinary retention. - Corticosteroids: may counteract diuretic effect, requiring dose adjustments.